Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

91.89 +2.27 (+2.53%)
Streaming Delayed Price Updated: 1:55 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
From BioNTech SE
Via GlobeNewswire
News headline image
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire
News headline image
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Host Innovation Series R&D Day on November 11, 2025
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025
From BioNTech SE
Via GlobeNewswire
News headline image
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
From BioNTech SE
Via GlobeNewswire
News headline image
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Ryan Richardson to Step Down from the Management Board
From BioNTech SE
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CureVac N.V. (Nasdaq - CVAC), Know Labs, Inc. (NYSE American - KNW), Volato Group, Inc. (NYSE American - SOAR), Heliogen, Inc. (OTC - HLGN)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
From BioNTech SE
Via GlobeNewswire
News headline image
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.